A User Performance and System Use Evaluation of a New Blood Glucose Monitoring System ( BGMS)

NCT ID: NCT03851549

Last Updated: 2019-03-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

360 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-12

Study Completion Date

2019-04-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is the US Regulatory Clinical Evaluation - User Performance and System Use Evaluation of a new Blood Glucose Monitoring System (BGMS).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

User Performance - Assess Lay User fingertip test results obtained on the new BGMS compared to a validated method (YSI 2300 STAT PLUS glucose analyzer results) according to FDA Guidance 2016 section VI.C.

Assess System Use of the new BGMS, as relevant to self-testing technique, with reference to the Owner's Booklet.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Blood Glucose monitoring System (BGMS)

Intervention: Blood Glucose monitoring Systems (BGMS): Results obtained from the new BGMS for UP are compared to a reference instrument (YSI 2300)

Group Type EXPERIMENTAL

New BGMS (US)

Intervention Type DEVICE

New blood glucose monitoring system / In vitro diagnostic device (IVDD)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

New BGMS (US)

New blood glucose monitoring system / In vitro diagnostic device (IVDD)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subject is at least 12 years old. Informed Consent. Subject has a current diagnosis of type 1 or type 2 diabetes mellitus. Subject reads and understands English. Subject is currently performing unassisted self-monitoring of blood glucose (SMBG) OR naive to SMBG for a 10% sub-group.

Exclusion Criteria

Conflict of interest. Technical expertise.
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut für Diabetes-Technologie ( IfDT)

UNKNOWN

Sponsor Role collaborator

LifeScan Scotland Ltd

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kirsty Macleod

Role: STUDY_DIRECTOR

LifeScan Scotland

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institut für Diabetes-Technologie

Ulm, , Germany

Site Status

Royal Infirmary of Edinburgh

Edinburgh, Lothian, United Kingdom

Site Status

Birmingham Heartlands Hospital

Birmingham, , United Kingdom

Site Status

Centre for Health Science

Inverness, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Lorna Stewart

Role: CONTACT

+44 01463 721000

Laura Ritchie

Role: CONTACT

+44 01463 721000

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Annnette Baumstark

Role: primary

Barry Irvine

Role: backup

Barry Irvine

Role: primary

Laura Ritchie

Role: primary

Danielle King

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Katz LB, Stewart L, King D, Cameron H. Meeting the New FDA Standard for Accuracy of Self-Monitoring Blood Glucose Test Systems Intended for Home Use by Lay Users. J Diabetes Sci Technol. 2020 Sep;14(5):912-916. doi: 10.1177/1932296820906184. Epub 2020 Feb 14.

Reference Type DERIVED
PMID: 32059615 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3178226

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Home Use Sensor Study
NCT02932514 UNKNOWN NA
System Accuracy of BGM GL22
NCT06146933 COMPLETED NA